FDA peptide compounding status and safety signals

Clinical Question

What is the current regulatory status of commonly compounded peptides and what are the emerging safety signals from post-marketing surveillance and clinical trials?

Evidence Snapshot

• Regulatory Status: Multiple peptides including BPC-157, TB-500, and Ipamorelin are currently listed as FDA Category 2 bulk substances as of March 2026.
• Compounding Restrictions: Several substances previously nominated for 503A compounding, such as CJC-1295 and AOD-9604, have had nominations withdrawn or have been removed as of September 2024.
• Safety Signals: Semaglutide surveillance shows strong gastrointestinal signals (Nausea, Vomiting) and emerging signals for NAION and Pulmonary Aspiration.
• Clinical Outcomes: Phase III data for approved GLP-1 and GIP/GLP-1 agonists show weight loss ranging from 14.9% to 22.5%, while specific peptides like Thymosin Alpha-1 show negative results in sepsis mortality trials.

What the Research Shows

Regulatory and Compounding Landscape As of March 2026, the FDA has classified several therapeutic peptides under Category 2 (September 2023), identifying them as having significant safety risks and making them ineligible for routine compounding. BPC-157 is currently noted for immunogenicity concerns and a lack of safety data. Similarly, TB-500 (Thymosin Beta-4) is cited for immunogenicity risk and a lack of human exposure data.

Regulatory shifts occurred in September 2024 concerning 503A statuses. Nominations for AOD-9604, Ipamorelin, and Selank were withdrawn. CJC-1295 was removed from consideration due to FDA-cited safety issues, specifically increased heart rate. Thymosin Alpha-1 was moved from Category 2 to being removed pending advisory review in September 2024, although it remains a substance of concern under interim policy.

Safety Signal Analysis Post-marketing data for Semaglutide (recorded through 187,757 GLP-1 receptor agonist reports) indicates strong signals for nausea, vomiting, and delayed gastric emptying. The FDA recently added Intestinal Obstruction/Ileus to the label. Emerging signals currently under evaluation include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, and Pulmonary Aspiration, which was added to the Ozempic label in 2025 due to risks during general anesthesia.

Clinical Trial Results Large-scale Phase III trials have established efficacy benchmarks for metabolic peptides. The STEP 1 trial demonstrated 14.9% weight loss for Semaglutide, while the SURMOUNT-1 trial for Tirzepatide showed 22.5% weight loss. In contrast, Thymosin Alpha-1 failed to show a reduction in mortality in the Phase III TESTS trial for sepsis (PMID: 39814420).

Mechanism

Mechanistic data provided focuses on clinical outcomes and adverse event profiles. For Semaglutide, delayed gastric emptying is a documented physiological effect that contributes to both therapeutic impact and clinical concerns regarding oral medication absorption and pre-surgical aspiration. For CJC-1295, a reported physiological response includes an increased heart rate. Immunogenicity is a primary cited risk mechanism for bulk substances including BPC-157, TB-500, GHK-Cu, and GHRP-2.

Limitations of the Evidence

There is a notable lack of human exposure data for several compounds currently used in compounding, specifically TB-500. While Semaglutide has extensive surveillance data, signals such as Suicidal Ideation and NAION remain under formal evaluation or review by agencies like the EMA and FDA to determine if they exceed background risks. Many peptides, including Selank and Semax, are approved in other jurisdictions (Russia) but lack FDA approval, limiting the availability of standardized safety data in the United States. Additionally, some clinical trials, such as the TRIUMPH-3 (Retatrutide) and STAY Trial (Tesamorelin), are ongoing with results not yet available.

Clinical Takeaway

Physicians should note that many peptides previously available via compounding (BPC-157, CJC-1295, TB-500) are currently classified by the FDA as Category 2 substances due to concerns over immunogenicity and lack of safety data. For approved therapies like Semaglutide, clinical focus is shifting toward managing post-marketing signals including pulmonary aspiration risk during anesthesia and newly labeled gastrointestinal complications like ileus.

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Sources

1. FDA Regulatory Status Record: BPC-157 (ID: 0abdad3c)
2. FDA Regulatory Status Record: Thymosin Alpha-1 (ID: 68b0b103)
3. FDA Regulatory Status Record: CJC-1295 (ID: 1a160b34)
4. FAERS Safety Signal: Semaglutide (IDs: 502f8ab5, 60c7beaa, be753983)
5. Clinical Trial Record: NCT03548935 (STEP 1)
6. Clinical Trial Record: NCT04184622 (SURMOUNT-1)
7. Clinical Trial Record: NCT02867267 (Thymosin Alpha-1 Sepsis)